Market Place
Sourcing Support
Pharnext blames ‘unexpected’ placebo results for phase 3 failure
11 Dec 2023 //
FIERCE BIOTECH
Pharnext ditches Alzheimer’s plans to save cash
14 Feb 2023 //
FIERCE BIOTECH
Pharnext Appoints Scott Johnson as VP, Head of Quality
04 Jan 2023 //
ACCESSWIRE
Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps Development
29 Dec 2022 //
BIOSPACE
Pharnext Acknowledges the Resignation of Dr. David Horn SOLOMON as CEO
28 Nov 2022 //
ACCESSWIRE
Pharnext Acknowledges Resignation of Dr. David Horn SOLOMON as CEO
28 Nov 2022 //
ACCESSWIRE
Hugo Brugière Joins Pharnext Board of Directors
08 Nov 2022 //
ACCESSWIRE
Pharnext Announces Neovacs Has Set Up Trust for Pharnext Securities Issued
31 Oct 2022 //
ACCESSWIRE
Pharnext Reports First Half 2022 Financial Results
17 Oct 2022 //
ACCESSWIRE
Pharnext Announces a Reverse Stock Split and Suspension of the Right to Exercise
03 Oct 2022 //
ACCESSWIRE
Pharnext Executes a Financing Agreement with Néovacs for EUR 20.7 million
03 Oct 2022 //
ACCESSWIRE
Pharnext: Findings From `Real-World` Digital Lifestyle Study, CMT&Me, on Symptom
13 Sep 2022 //
ACCESSWIRE
Pharnext Announces First Patient Enrolled Pivotal Ph III Study of PXT3003
12 Sep 2022 //
ACCESSWIRE
Pharnext Announces a €2.5m Loan Agreement with Néovacs
23 Aug 2022 //
BIOSPACE
Pharnext Announces Successful Debt Refinancing and New Loan Agreement
08 Jun 2022 //
ACCESSWIRE
Pharnext Announces On-Schedule Completion of PIII Trial of PXT3003
30 May 2022 //
ACCESSWIRE
Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
23 Dec 2021 //
PHARNEXT
Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
23 Dec 2021 //
PHARNEXT
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program
22 Dec 2021 //
ACCESSWIRE
Acorda CMO hits the exit, landing Pharnext job
25 Nov 2021 //
FIERCEBIOTECH
Data from Phase III Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A
18 Oct 2021 //
BIOSPACE
Alpha Blue Ocean & Pharnext announce signature of € 81M Financing agreement
10 Jun 2021 //
BUSINESSWIRE
Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows
28 Apr 2021 //
GLOBENEWSWIRE
Pharnext and the Charcot-Marie-Tooth Association Enter Biomarker Collaboration
03 Sep 2020 //
ACCESSWIRE
Pharnext Provides Regulatory and Clinical Update on PXT3003 Ph III Study
10 Jun 2020 //
BUSINESSINSIDER
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.